



Disposals of own shares

Brussels (Belgium), 17 July 2020 – 20:00 (CEST) – regulated information

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
10 July 2020	10:02:56	Stock Option Plan 2013	600	€ 48.69
10 July 2020	10:40:09	Stock Option Plan 2011	100	€ 26.72
10 July 2020	10:40:15	Stock Option Plan 2016	500	€ 67.24
10 July 2020	10:45:08	Stock Option Plan 2012	1000	€ 32.36
10 July 2020	10:45:08	Stock Option Plan 2013	100	€ 48.69
10 July 2020	10:45:08	Stock Option Plan 2012	500	€ 32.36
10 July 2020	12:00:41	Stock Option Plan 2014	1500	€ 58.12
10 July 2020	15:55:26	Stock Option Plan 2012	1300	€ 32.36
13 July 2020	12:16:00	Stock Option Plan 2013	4400	€ 48.69
13 July 2020	16:02:27	Stock Option Plan 2015	300	€ 67.35
13 July 2020	17:17:23	Stock Option Plan 2015	750	€ 67.35
14 July 2020	13:02:32	Stock Option Plan 2012	100	€ 32.36
14 July 2020	15:07:46	Stock Option Plan 2014	1000	€ 58.12
14 July 2020	15:30:14	Stock Option Plan 2011	100	€ 26.72
14 July 2020	15:42:55	Stock Option Plan 2013	1300	€ 48.69
14 July 2020	16:51:52	Stock Option Plan 2013	100	€ 48.69
15 July 2020	09:00:08	Stock Option Plan 2011	1100	€ 26.72
15 July 2020	11:00:53	Stock Option Plan 2011	100	€ 26.72
15 July 2020	11:00:53	Stock Option Plan 2012	200	€ 32.36
15 July 2020	11:00:53	Stock Option Plan 2013	100	€ 48.69
15 July 2020	11:00:54	Stock Option Plan 2011	1000	€ 26.72
15 July 2020	11:31:50	Stock Option Plan 2013	100	€ 48.69
15 July 2020	13:09:03	Stock Option Plan 2014	500	€ 58.12
16 July 2020	10:52:48	Stock Option Plan 2012	300	€ 32.36
16 July 2020	12:00:02	Stock Option Plan 2012	500	€ 32.36
16 July 2020	14:54:39	Stock Option Plan 2014	2,300	€ 58.12

This press release is available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: [@UCB_news](https://twitter.com/UCB_news)